Literature DB >> 33510344

Minor allele of GJA1 gene polymorphism is associated with higher heart rate during atrial fibrillation.

Sho Okamura1, Yuko Onohara1, Hidenori Ochi2,3, Takehito Tokuyama1, Naoya Hironobe1, Yosaku Okubo1, Yoshihiro Ikeuchi1, Shunsuke Miyauchi1, Kazuaki Chayama3, Yasuki Kihara1, Yukiko Nakano4.   

Abstract

Atrial fibrillation (AF) tachycardia causes heart failure and requires more attention. The genetic background of individual heart rate (HR) variations during AF are unclear. We hypothesized that HR-associated single nucleotide polymorphisms (SNPs) reported in Genome-Wide Association Studies (GWAS) are also associated with HR during AF. We enrolled patients with persistent AF (311 for screening and 146 for replication) who underwent AF ablation and were genotyped for the 21 h-associated SNPs reported in GWAS. The patients underwent 24-h Holter monitoring before AF ablation and electrophysiological study after AF ablation during sinus rhythm. Only the GJA1 SNP rs1015451 (T>C) was significantly associated with total HR (TT 110,643 ± 17,542 beats/day, TC 116,350 ± 19,060 beats/day, CC 122,163 ± 25,684 beats/day, P = 8.5 × 10-4). We also confirmed this significant association in the replication set. The intra-atrial conduction was faster in AF patients with the GJA1 minor allele than in those without it. Multivariate analysis revealed the presence of a GJA1 SNP rs1015451 additive model, female gender, lower left ventricular ejection fraction, and higher 1:1 atrioventricular nodal conduction were independently associated with higher HR during AF. The GJA1 SNP might be a new genetic marker for AF tachycardia.

Entities:  

Year:  2021        PMID: 33510344     DOI: 10.1038/s41598-021-82117-3

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  18 in total

1.  Non-invasive assessment of the effect of beta blockers and calcium channel blockers on the AV node during permanent atrial fibrillation.

Authors:  Frida Sandberg; Valentina D A Corino; Luca T Mainardi; Sara R Ulimoen; Steve Enger; Arnljot Tveit; Pyotr G Platonov; Leif Sörnmo
Journal:  J Electrocardiol       Date:  2015-07-26       Impact factor: 1.438

2.  Association of atrial fibrillation risk alleles and response to acute rate control therapy.

Authors:  Tyler W Barrett; Wesley H Self; Dawood Darbar; Cathy A Jenkins; Brian S Wasserman; Natasha A Kassim; Michael Casner; M Benjamin Shoemaker
Journal:  Am J Emerg Med       Date:  2016-02-10       Impact factor: 2.469

3.  2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.

Authors:  Paulus Kirchhof; Stefano Benussi; Dipak Kotecha; Anders Ahlsson; Dan Atar; Barbara Casadei; Manuel Castella; Hans-Christoph Diener; Hein Heidbuchel; Jeroen Hendriks; Gerhard Hindricks; Antonis S Manolis; Jonas Oldgren; Bogdan Alexandru Popescu; Ulrich Schotten; Bart Van Putte; Panagiotis Vardas
Journal:  Eur Heart J       Date:  2016-08-27       Impact factor: 29.983

Review 4.  Tachycardia mediated cardiomyopathy: pathophysiology, mechanisms, clinical features and management.

Authors:  Shuchita Gupta; Vincent M Figueredo
Journal:  Int J Cardiol       Date:  2014-01-08       Impact factor: 4.164

5.  Gender-related differences in rhythm control treatment in persistent atrial fibrillation: data of the Rate Control Versus Electrical Cardioversion (RACE) study.

Authors:  Michiel Rienstra; Dirk J Van Veldhuisen; Vincent E Hagens; Adelita V Ranchor; Nic J G M Veeger; Harry J G M Crijns; Isabelle C Van Gelder
Journal:  J Am Coll Cardiol       Date:  2005-10-04       Impact factor: 24.094

6.  Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study.

Authors:  A S Go; E M Hylek; K A Phillips; Y Chang; L E Henault; J V Selby; D E Singer
Journal:  JAMA       Date:  2001-05-09       Impact factor: 56.272

Review 7.  Rate control in atrial fibrillation.

Authors:  Isabelle C Van Gelder; Michiel Rienstra; Harry J G M Crijns; Brian Olshansky
Journal:  Lancet       Date:  2016-08-20       Impact factor: 79.321

8.  A genome-wide association study to identify genomic modulators of rate control therapy in patients with atrial fibrillation.

Authors:  Matthew J Kolek; Todd L Edwards; Raafia Muhammad; Adnan Balouch; M Benjamin Shoemaker; Marcia A Blair; Kaylen C Kor; Atsushi Takahashi; Michiaki Kubo; Dan M Roden; Toshihiro Tanaka; Dawood Darbar
Journal:  Am J Cardiol       Date:  2014-06-06       Impact factor: 2.778

9.  Prognostic Significance of Resting Heart Rate and Use of β-Blockers in Atrial Fibrillation and Sinus Rhythm in Patients With Heart Failure and Reduced Ejection Fraction: Findings From the Swedish Heart Failure Registry.

Authors:  Shi-Jun Li; Ulrik Sartipy; Lars H Lund; Ulf Dahlström; Martin Adiels; Max Petzold; Michael Fu
Journal:  Circ Heart Fail       Date:  2015-08-04       Impact factor: 8.790

Review 10.  Pathophysiology of gap junctions in heart disease.

Authors:  N J Severs
Journal:  J Cardiovasc Electrophysiol       Date:  1994-05
View more
  1 in total

1.  Association between the APOE gene polymorphism and lipid profile and the risk of atrial fibrillation.

Authors:  Xunwei Deng; Jingyuan Hou; Qiaoting Deng; Zhixiong Zhong
Journal:  Lipids Health Dis       Date:  2021-09-29       Impact factor: 3.876

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.